In linear IgA bullous dermatosis, oral dapsone — with or without a potent topical corticosteroid — is the established first-line treatment. When this approach does not bring the disease to the defined clinical endpoint, a second-line strategy is indicated.
The prior step — oral dapsone, with or without clobetasol propionate topical therapy — did not achieve the required goal: negative direct immunofluorescence obtained from a previously positive lesion site.
Failure to reach this endpoint is the basis for escalating to the protocol described here.
Several second-line agents are available to use in combination with dapsone, or as alternatives, when first-line therapy has not achieved the treatment goal. The complete evidence-based selection, sequencing, and clinical decision logic are in the full protocol.
DOI: 10.1111/jdv.19880
When it leads to a partial response, other drugs may be used in combination with dapsone.
Sulfonamides, including sulfapyridine, sulfasalazine and sulfamethoxypyridazine, are alternatives to dapsone and may be used alone or in combination with it.
View source ↗